---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-015586"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:17:30.986844+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxart reports Q1 net income $5.2M; COVID-19 sentinel data expected Q2 2026

## Summary
- Q1 2026 net income $5.2M ($0.02/sh) vs net loss ($15.6M) in Q1 2025.
- Revenue $39.2M (+87% YoY) mainly from BARDA contract and Dynavax license.
- Cash $61.0M provides runway into Q2 2027; Lincoln Park equity facility up to $25M.
- Topline sentinel data from Phase 2b COVID-19 trial (400 participants) anticipated in Q2 2026.
- Appointed Dr. James B. Breitmeyer to board; relocated HQ to reduce overhead.

## SEC filing metadata
- accession: 0001437749-26-015586
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774926015586/0001437749-26-015586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774926015586/vxrt20260507_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-015586
- JSON: https://secwatch.observer/filing/0001437749-26-015586.json
- Plain text: https://secwatch.observer/filing/0001437749-26-015586.txt

## Source-grounded claims
- claim_id: 0ba2841e72caa9e26d3461305c67dcf5f82f8431
  claim: Vaxart, Inc. reported the first quarter of 2026 results: revenue $39.2 million, net income $5.2 million, EPS $0.02.
  evidence_excerpt: funding options, with the goal of achieving its upcoming clinical and regulatory milestones and maximizing stockholder value. ● Revenue for the first quarter of 2026 was $39.2 million, compared to $20.9 million for the first quarter of 2025. Revenue in the first quarter of 2026 and the first quarter of 2025 was primarily from government contracts related to
  evidence_url: https://www.sec.gov/Archives/edgar/data/72444/000143774926015586/0001437749-26-015586-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.